New trial explores whether EBV vaccine can slow early MS activity
A clinical trial is now recruiting participants to test whether an experimental vaccine for the Epstein-Barr virus (EBV) is…
Articles by Marisa Wexler, MS
Mesenchymal stem cell therapy shows promise for MS: Review
Mesenchymal stem cell therapy shows promise for treating multiple sclerosis (MS), with improvements seen in disability, walking ability,…
New method shines light on nerve fibers in the brain
A new technique is letting scientists peer into the brain’s wiring with greater detail by simply using a microscope and…
MS drug fenebrutinib shows ‘unprecedented results’ in trials
Genentech‘s experimental oral therapy fenebrutinib has become the first Bruton’s tyrosine kinase (BTK) inhibitor to show positive Phase…
Wearable sensors move MS brain imaging beyond MRI machines
A new wearable brain-mapping tool could dramatically change how doctors monitor people with multiple sclerosis (MS), making it easier…
New imaging tool detects damaged myelin across large brain areas
Researchers have developed a highly sensitive imaging technique that can detect damage to myelin, the fatty wrapping around nerve…
Ultraviolet B therapy may help stabilize MS inflammation
Ultraviolet light therapy may help reduce inflammation and disease severity in people with multiple sclerosis (MS), according to data…
Antibodies against Epstein-Barr virus don’t predict MS progression
People with multiple sclerosis (MS) tend to have high levels of antibodies targeting the Epstein-Barr virus (EBV), but…
Quality of life lower for people with MS regardless of age, gender
People living with multiple sclerosis (MS) have consistently lower quality of life than the general population — regardless of…
Stigma keeps many with chronic health issues in a hidden struggle
A third of adults live with chronic physical conditions such as multiple sclerosis (MS), but in most cases these…
High-carb diet may raise MS risk, especially for women: Study
Eating more carbohydrates is significantly associated with a higher risk of developing multiple sclerosis (MS), particularly among women and…
Makeup of bacteria in the mouth is altered in MS, new study finds
People with multiple sclerosis (MS) have altered levels of bacteria in their mouths, with reduced levels of normal healthy…
MS brain damage starts years before symptoms appear: Study
Signs of myelin damage are detectable about one year before damage to nerve fibers is apparent and about seven years…
Targeting abnormal brain cells may be key to treating progressive MS
Abnormal brain cells, known as disease-associated radial glia or DARGs, may play a key role in driving chronic inflammation in…
Myelin damage may lead to seizures in MS, mouse study finds
Seizures in people with multiple sclerosis (MS) may be driven by changes in levels of certain brain signaling molecules,…
Two compounds with potential for myelin repair in MS identified
Researchers have identified two experimental medications that may promote myelin repair in people with multiple sclerosis (MS). The two…
Zenas acquires BTK inhibitor in Phase 3 trials for progressive MS
Zenas Biopharma has acquired global rights to develop the BTK inhibitor orelabrutinib to treat multiple sclerosis (MS) and…
ECTRIMS 2025: Briumvi keeps MS patients relapse-free for 6 years
Up to six years of continuous treatment with Briumvi (ublituximab) led to sustained reductions in relapse rates and a…
ECTRIMS 2025: Standard Ocrevus dose holds up in PPMS
Increasing the dose of Ocrevus (ocrelizumab) by two- or threefold, depending on a person’s weight, did not provide additional…
ECTRIMS 2025: Long-term benefits seen with Mavenclad use in MS
Most people with relapsing forms of multiple sclerosis (MS) given Mavenclad (cladribine) did not experience confirmed disability progression…
ECTRIMS 2025: Eque-cel shown to ease disability in progressive MS
Treatment with equecabtagene autoleucel, known for short as eque-cel — Iaso Biotherapeutics‘ CAR T-cell therapy candidate for people with…
ECTRIMS 2025: Drug combo shows promise for myelin repair in trial
Combining the diabetes medication metformin and the antihistamine clemastine significantly increased myelin repair in people with relapsing-remitting multiple sclerosis…
ECTRIMS 2025: Aerobic exercise may promote myelin repair in MS
Aerobic exercise may help promote myelin repair in some parts of the brain in people with multiple sclerosis (MS),…
ECTRIMS 2025: MIND diet may help reduce MS fatigue, disability
Following the MIND diet, a program that focuses on brain health, may help reduce disability, ease fatigue, and improve quality…
ECTRIMS 2025: Updated McDonald criteria enable more MS diagnoses
The new revisions to the McDonald criteria for multiple sclerosis (MS) — a set of guidelines long used…
FDA pushes back to December its decision on Sanofi’s tolebrutinib
Note: This story was updated Sept. 23, 2025, to correct the generic name of Aubagio from tolebrutinib to teriflunomide. The…
New McDonald criteria aim for faster MS diagnosis, treatment
Doctors will be able to diagnose multiple sclerosis (MS) faster and with greater accuracy — allowing patients to access…
Paramagnetic rim lesions could help in diagnosing MS early: Study
Paramagnetic rim lesions (PRLs), which represent areas of damage in the brain and spinal cord with chronic active inflammation, are…
New patent covers progressive MS drug for patients in US
Immunic Therapeutics will receive a new U.S. patent covering its experimental therapy, vidofludimus calcium, and some related molecules in people with…
Most MS neurologists in the US have received pharma payments
In the U.S., nearly 4 out of 5 neurologists prescribing therapies for multiple sclerosis (MS) have received payments from…